Planta Med 2012; 78 - PD47
DOI: 10.1055/s-0032-1320405

4'-Geranyloxyferulic Acid-L-name prodrug inhibits inflammation-related colorectal carcinogenesis in mice

T Tanaka 1, S Genovese 2, T Kochi 3, F Epifano 2, L Scauri 2, M Curini 4, M Shimizu 3, H Moriwaki 3
  • 1Departments of Tumor Pathology
  • 3Internal Medicine, Gifu University School of Medicine, Gifu, Japan
  • 2Dipartimento di Scienze del Farmaco, Università “G. D'Annunzio” Chieti-Pescara, Chieti, Italy
  • 4Dipartimento di Chimica e Tecnologia del Farmaco, Università degli Studi di Perugia, Perugia, Italy

We previously reported cancer chemopreventive ability of the naturally occurring cinnamic acid derivative 4'-geranyloxyferulic acid (GOFA) and two β-cyclodextrin inclusion compound of GOFA in colorectal carcinogenesis.1,2 In this study, potential cancer chemopreventive ability of a newly synthesized prodrug, GOFA-L-NAME, was investigated using a colitis-associated mouse colorectal carcinogenesis model with azoxymethane (AOM) and dextran sodium sulfate (DSS).3,4 The dietary administration of GOFA-L-NAME significantly reduced the multiplicity of adenocarcinomas (inhibition rates: 100 ppm, 84%, p<0.001; and 500 ppm, 94%, p<0.001), when compared with the AOM+DSS group. Subsequent short-term experiment revealed that dietary GOFA-L-NAME lowered mRNA expression of pro-inflammatory cytokines and inflammatory enzymes in colonic mucosa of mice that received 1.5% DSS in drinking for 7 days. Our findings will be presented.


1. Miyamoto, S. et al. Nutr. Canc. 2008, 5, 675; 2. Tanaka, T. et al. Int. J. Cancer, 2010, 126, 830; 3. Kawamori et al., Cancer Lett. 2000, 148, 33; 4. Tanaka, T. et al. Cancer Sci. 2003, 94, 965; 5. Tanaka T. Int. J. Inflammation 2012, Article ID 658786.